Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Duncansville, PA
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
San Antonio, TX
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
St. Petersburg, FL
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Lincoln, NE
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Tuscon, AZ
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Sacramento, CA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Englewood, CO
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Dover, DE
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Dover, DE
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Lighthouse Point, FL
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Lighthouse Point, FL
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Tampa, FL
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Atlanta, GA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Savannah, GA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Chicago, IL
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Evanston, IL
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Des Moines, IA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Des Moines, IA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Lenexa, KA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Lenexa, KA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Lexington, KY
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Louisville, KY
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Baton Rouge, LA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Annapolis, MD
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Annapolis, MD
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Baltimore, MD
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Lexington, MA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Lexington, MA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Springfield, MA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Springfield, MA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Worcester, MA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Clinton Township, MI
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Clinton Township, MI
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Muskegon, MI
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Muskegon, MI
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Golden Valley, MN
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Columbia, MO
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Great Falls, MT
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Great Falls, MT
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Lincoln, NE
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Omaha, NE
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Freehold, NJ
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Bronx, NY
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
New York, NY
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Patchogue, NY
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Patchogue, NY
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Asheville, NC
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Hickory, NC
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Raleigh, NC
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Akron, OH
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Canton, OH
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Columbus, OH
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Medford, OR
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Portland, OR
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Abington, PA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Abington, PA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Greensburg, PA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Greensburg, PA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Knoxville, TN
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials